DPx Holdings B.V., the parent company of pharmaceutical services company Patheon, announced Tuesday that it has completed its acquisition of Gallus BioPharmaceuticals.
Gallus is a contract manufacturing company that specializes in biologics. Gallus will become part of Patheon’s biologics drug substance business, which is a unit of Durham-based DPx Holdings.
The business employs more than 550 employees and has facilities in Europe, Australia and North America. Patheon manufactures drugs for pharmaceutical companies and also provides services, such as developing formulations of experimental medicines.
“This acquisition allows us to better serve the biologics segment in our industry and aligns with our strategy to continue to bring our customers an industry leading end-to-end service offer,” DPx Holdings CEO Jim Mullen said in a statement.
DPx Holdings was created earlier this year as a result of the merger of Durham-based Patheon and DSM Pharmaceutical Products. The deal ended Patheon’s stint as a public company. JLL Partners, a private equity firm that owned a controlling stake in Patheon, owns 51 percent of DPx Holdings while Royal DSM, a vitamin company based in the Netherlands, owns the rest.
DPx has more than 8,000 worldwide employees.